Results 101 to 110 of about 416,036 (340)

AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway

Journal of Experimental & Clinical Cancer Research, 2019
Background Cisplatin is the first-line chemotherapy used against most upper aerodigestive tract carcinomas. In head and neck cancer, sensitivity to cisplatin remains the key issue in treatment response and outcome. Genetic heterogeneity and aberrant gene
Wei-Min Chang, Yu-Chan Chang, Yi-Chieh Yang, Sze-Kwan Lin, Peter Mu-Hsin Chang, Michael Hsiao   +5 more
doaj   +1 more source

Reconfigurable Nucleic Acid Nanoparticles with Therapeutic RNAi Responses to Intracellular Disease Markers

Advanced Functional Materials, EarlyView.
Many known diseases arise from dysregulated gene expression, and differentially expressed genes can serve as biomarkers to distinguish diseased cells from healthy tissues. In this study, reconfigurable nucleic acid nanoparticles (recNANPs) are introduced that can detect overexpressed cancer biomarkers and subsequently release RNAi inducers to silence ...
Yelixza I. Avila, Anh Ha, Morgan R. Chandler, Nathalia Leal Santos, Taejin Kim, Hannah S. Newton, Marina A. Dobrovolskaia, Kirill A. Afonin   +7 more
wiley   +1 more source

Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma

Molecular & Cellular Oncology
Cisplatin is the commonly used chemotherapeutic drug in treatment of various cancers. However, development of resistance towards cisplatin results in tumor recurrence.
Ankit P. Jain, Vivek Ghose, Srijon Munshi, Firdous A. Bhat, Gourav Dey, Vishalakshi Nanjappa   +5 more
doaj   +1 more source

MECHANISM OF APOPTOSIS INHIBITION TO SQUAMOUS CELL CARCINOMA OF ORAL CANCER IN CISPLATIN TREATMENT

Folia Medica Indonesiana, 2017
This study was to approve the increased secretion of Hsp 70, DNA damage, and inhibitor apoptosis protein in cisplatin therapy which influence apoptosis of oral cancer cell and to know mechanism of molecular pathology.
R Marjono Dwi Wibowo, David S Perdanakusuma, Eddy Herman Tanggo   +2 more
doaj   +1 more source

Safety evaluation of low level light therapy on cancer cells [PDF]

, 2016
OBJECTIVE: Low level light therapy (LLLT) is being widely used in wound healing and pain relief, and its use is expected to be expanded rapidly to treatment of other disorders as well in a foreseeable future.
Jeong, Andrew S.
core   +1 more source

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life [PDF]

, 2004
BACKGROUND: In 1995 a meta-analysis of randomised trials investigating the value of adding chemotherapy to primary treatment for non-small cell lung cancer (NSCLC) suggested a small survival benefit for cisplatin-based chemotherapy in each of the primary
Brown, J., Fairlamb, D.J., Gower, N.H., Maslove, L., Milroy, R., Napp, V., Parmar, M.K.B., Peake, M.D., Rudd, R.M., Souhami, R.L., Spiro, S.G., Stephens, R.J., Thorpe, H., Waller, D.A., West, P.   +14 more
core   +2 more sources

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Glutathione S‐transferase omega class 1 (GSTO1)‐associated large extracellular vesicles are involved in tumor‐associated macrophage‐mediated cisplatin resistance in bladder cancer

Molecular Oncology
Bladder cancer poses a significant challenge to chemotherapy due to its resistance to cisplatin, especially at advanced stages. Understanding the mechanisms behind cisplatin resistance is crucial for improving cancer therapy.
Yi‐Cheng Pan, Pei‐Yi Chu, Ching‐Chan Lin, Ching‐Yun Hsieh, Wei‐Yu Hsu, Lie‐Fen Shyur, Juan‐Cheng Yang, Wei‐Chao Chang, Yang‐Chang Wu   +8 more
doaj   +1 more source

Fluorescent Nanodiamonds Based Theranostic Platform for pH‐Sensitive Drug Delivery and Quantum Sensing

Advanced Functional Materials, EarlyView.
A multifunctional nanodiamond platform enables pH‐triggered Diazoxide (DZX) delivery and quantum sensing of subcellular radical dynamics in triple‐negative breast cancer cells. Diamond relaxometry revealed reduced lysosomal radicals during DZX‐induced mitochondrial radical elevation, providing insights into redox modulation and organelle‐ resolved ...
Kaiqui Wu, Siyu Fan, Yue Zhang, Willem Woudstra, Thomas Mulder, Laurens Boscher Navarro, Jur van Dijken, Katja Loos, Romana Schirhagl   +8 more
wiley   +1 more source

MTMR6 downregulation contributes to cisplatin resistance in oral squamous cell carcinoma

Cancer Cell International
Background The therapeutic effectiveness of cisplatin, a widely used chemotherapy drug for oral squamous cell carcinoma (OSCC), is often compromised by resistance, making it difficult to predict treatment outcomes.
Kah Young Lee, Su Young Oh, Heon-Jin Lee, Tae-Geon Kwon, Jin-Wook Kim, Chang-Geol Shin, Su-Hyung Hong, So-Young Choi   +7 more
doaj   +1 more source